IN VIVO

metrics 2024

Exploring the frontiers of pharmacology and genetics.

Introduction

IN VIVO is a prestigious academic journal published by the International Institute of Anticancer Research, dedicated to advancing the fields of biochemistry, genetics, molecular biology, cancer research, and pharmacology. With its ISSN 0258-851X and E-ISSN 1791-7549, this journal has been a key contributor to innovative research since its inception in 1987, providing a crucial platform for the dissemination of significant findings in its scope. With an impressive impact reflected in its quartile rankings (Q2 in Biochemistry, Genetics and Molecular Biology and Medicine; Q3 in Cancer Research and Pharmacology), IN VIVO reaches a global audience comprising researchers, health professionals, and students. Although it operates on a subscription basis, the journal’s commitment to scientific excellence and rigorous peer review ensures that all published works maintain high quality and relevance. Notably positioned in Scopus ranks within the 36th to 59th percentiles across various categories, IN VIVO continues to be a vital resource for cutting-edge research and developments, solidifying its importance within the scientific community.

Metrics 2024

SCIMAGO Journal Rank0.56
Journal Impact Factor1.80
Journal Impact Factor (5 years)1.90
H-Index72
Journal IF Without Self1.80
Eigen Factor0.01
Normal Eigen Factor1.38
Influence0.41
Immediacy Index0.40
Cited Half Life4.40
Citing Half Life7.40
JCI0.48
Total Documents4709
WOS Total Citations5847
SCIMAGO Total Citations20282
SCIMAGO SELF Citations1409
Scopus Journal Rank0.56
Cites / Document (2 Years)1.88
Cites / Document (3 Years)2.08
Cites / Document (4 Years)2.11

Metrics History

Rank 2024

Scopus

General Biochemistry, Genetics and Molecular Biology in Biochemistry, Genetics and Molecular Biology
Rank #91/221
Percentile 58.82
Quartile Q2
Pharmacology in Pharmacology, Toxicology and Pharmaceutics
Rank #169/313
Percentile 46.01
Quartile Q3
Cancer Research in Biochemistry, Genetics and Molecular Biology
Rank #147/230
Percentile 36.09
Quartile Q3

IF (Web Of Science)

MEDICINE, RESEARCH & EXPERIMENTAL
Rank 130/189
Percentile 31.50
Quartile Q3

JCI (Web Of Science)

MEDICINE, RESEARCH & EXPERIMENTAL
Rank 127/189
Percentile 32.80
Quartile Q3

Quartile History

Similar Journals

NEOPLASMA

Connecting Researchers for a Cancer-Free Future
Publisher: AEPRESS SROISSN: 0028-2685Frequency: 6 issues/year

NEOPLASMA is a prominent journal published by AEPRESS SRO, dedicated to the multifaceted field of oncology and cancer research. Since its inception in 1957, this esteemed publication has served as a vital platform for advancing the understanding of neoplastic diseases, disseminating high-quality research findings that contribute to clinical and laboratory advancements. Operating under a robust framework of peer review, NEOPLASMA holds significant credibility, as evidenced by its Q2 ranking in the Medicine (miscellaneous) category and Q3 rankings in both Cancer Research and Oncology for 2023. Furthermore, with an ISSN of 0028-2685 and E-ISSN 1338-4317, the journal fosters accessibility to valuable scientific content despite the absence of open access options. Positioned in Bratislava, Slovakia, NEOPLASMA continues to attract a global readership, making substantial contributions to the fields of biochemistry, genetics, and molecular biology as highlighted by its Scopus rankings. This journal is essential reading for researchers, professionals, and students looking to stay abreast of the latest developments in cancer research and treatment strategies.

ANTICANCER RESEARCH

Shaping Tomorrow’s Cancer Therapies Today
Publisher: INT INST ANTICANCER RESEARCHISSN: 0250-7005Frequency: 12 issues/year

ANTICANCER RESEARCH, published by the International Institute of Anticancer Research, stands at the forefront of cancer-related scholarly communication. With ISSN 0250-7005 and E-ISSN 1791-7530, this esteemed journal has been serving the global research community since 1981, showcasing innovative research aimed at combating cancer through various therapeutic approaches and scientific inquiry. Based in Greece, the journal aims to disseminate vital findings in the fields of Cancer Research, Medicine, and Oncology, reflecting its notable categorization in the Q3 and Q2 quartiles as of 2023. Despite its rigorous peer-review process and the absence of open access, ANTICANCER RESEARCH remains a vital publication for researchers, clinicians, and students eager to stay updated on the evolving landscape of anticancer strategies. As it converges to its milestone year of 2024, the journal continues to enrich the discourse around cancer treatment and prevention, affirming its position as an essential resource for those dedicated to advancing knowledge in anticancer therapies.

Cell Reports Medicine

Advancing biomedical knowledge for a healthier tomorrow.
Publisher: CELL PRESSISSN: 2666-3791Frequency: 12 issues/year

Cell Reports Medicine, published by Cell Press, represents a pivotal advancement in the open access landscape of biomedical research since its inception in 2020. With a dedicated focus on the intersection of medicine, biochemistry, genetics, and molecular biology, this journal has quickly established itself as a key resource, earning a remarkable Q1 ranking in these fields. Based in the United States, Cell Reports Medicine boasts impressive metrics, ranking #25 out of 636 in General Medicine and #18 out of 221 in Biochemistry, underscoring its influence and reach within the scientific community, with a notable 96th and 92nd percentile respectively. As a fully open access journal, it fosters global dissemination of knowledge, ensuring that groundbreaking research is readily available to researchers, professionals, and students alike. The journal not only promotes high-quality research but also aims to bridge the gap between molecular discoveries and clinical applications, making it an essential addition to any academic library or researcher's toolkit.

EXPERIMENTAL AND MOLECULAR PATHOLOGY

Unraveling molecular mysteries in pathology.
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCEISSN: 0014-4800Frequency: 6 issues/year

EXPERIMENTAL AND MOLECULAR PATHOLOGY, a distinguished journal published by Academic Press Inc Elsevier Science, is recognized for its significant contributions to the fields of pathology, clinical biochemistry, and molecular biology. With an ISSN of 0014-4800 and an E-ISSN of 1096-0945, this journal provides a platform for the dissemination of high-quality research articles, reviews, and experimental studies that deepen our understanding of disease mechanisms and diagnostic pathways. Since its inception in 1962 and through its converged publication years, the journal has consistently maintained a solid impact in the academic community, achieving high Scopus rankings—ranked #15 in the field of Pathology and Forensic Medicine and #22 in Clinical Biochemistry, showcasing a commendable percentile standing of 93rd and 81st respectively in 2023. The journal is accessible through various academic libraries and institutional subscriptions, making it an essential resource for researchers, professionals, and students committed to advancing knowledge in these critical areas. With a categorization that includes Q1 rankings in Pathology and Forensic Medicine, EXPERIMENTAL AND MOLECULAR PATHOLOGY stands as a prominent venue for pioneering scientific inquiry and collaborative advancement in molecular diagnostics and therapeutic strategies.

JOURNAL OF BIOMEDICAL SCIENCE

Leading the way in biomedical research and collaboration.
Publisher: BMCISSN: 1021-7770Frequency: 1 issue/year

JOURNAL OF BIOMEDICAL SCIENCE, published by BMC, is a premier Open Access journal dedicated to the rapid dissemination of research in the fields of biomedical science, encompassing crucial areas such as biochemistry, cell biology, clinical biochemistry, and more. Since its inception in 1993, the journal has established itself as a leading publication, currently boasting a remarkable impact factor and quality as evidenced by its Q1 quartile rankings across multiple categories in 2023. With an impressive track record, including a Scopus ranking in the top percentiles across several disciplines, it serves as a vital resource for researchers, professionals, and students who are keen on advancing their knowledge in biomedicine. The journal operates under a fully Open Access model, ensuring that all published articles are freely available to the global research community, thus contributing to the broader dissemination and accessibility of scientific knowledge. Based in the United Kingdom, JOURNAL OF BIOMEDICAL SCIENCE is committed to fostering innovation and collaboration in research, appealing to those aiming to make impactful contributions to the biomedical sphere.

Biomed Research International

Pioneering interdisciplinary research in health and disease.
Publisher: HINDAWI LTDISSN: 2314-6133Frequency: 1 issue/year

Biomed Research International is a prominent open access journal published by HINDAWI LTD, dedicated to advancing the field of biomedical research. With its ISSN 2314-6133 and E-ISSN 2314-6141, this journal has been a significant contributor to the scientific community since its inception in 2013, making scholarly work accessible to a global audience. The journal's scope encompasses a range of disciplines, including biochemistry, genetics, molecular biology, immunology, microbiology, and medicine, reflecting its commitment to interdisciplinary research. Ranked in the Q2 quartile as of 2023 across several relevant categories, Biomed Research International is recognized for its high-quality publications that foster innovation and collaboration in biomedical studies. Researchers, professionals, and students looking to share and gain insights into cutting-edge biomedical discoveries will find this journal an essential resource. With a focus on rapid dissemination of research findings, the journal serves as a vital platform for academics to engage with contemporary issues in health and disease, ultimately contributing to the advancement of medical science.

M S-MEDECINE SCIENCES

Unveiling critical advancements in biochemistry and medicine.
Publisher: EDP SCIENCES S AISSN: 0767-0974Frequency: 12 issues/year

M S-MEDECINE SCIENCES, published by EDP SCIENCES S A, is an esteemed journal based in France dedicated to the fields of biochemistry, genetics, and medicine. With an ISSN of 0767-0974 and an E-ISSN of 1958-5381, this journal has been a platform for scholarly communication since its inception in 1990 and continues to present critical advancements in these scientific domains, aiming to bridge theoretical research with practical applications. Despite its current Q4 ranking in both Biochemistry, Genetics and Molecular Biology and Medicine categories, the journal aspires to enhance its visibility and impact within the academic community. Researchers and professionals can benefit from a wealth of studies that contribute to the understanding of complex biological systems and medical innovations. Interested authors are encouraged to explore the journal's submission guidelines and contribute to the growing body of knowledge in these important fields.

Sovremennye Tehnologii v Medicine

Bridging Research and Practice in Modern Medicine
Publisher: NIZHNIY NOVGOROD STATE MEDICAL ACADISSN: 2076-4243Frequency: 6 issues/year

Sovremennye Tehnologii v Medicine is a prominent academic journal dedicated to the exploration and dissemination of contemporary technologies in the field of medicine. Published by the esteemed Nizhniy Novgorod State Medical Academy, this journal serves as a vital platform for researchers, healthcare professionals, and students seeking to stay at the forefront of advancements in biochemistry, genetics, and molecular biology. With an impact factor that positions it within the Q3 quartile for both Biochemistry, Genetics and Molecular Biology and Medicine categories as of 2023, it highlights a commitment to quality research. The journal, identified by the ISSN 2076-4243, provides a rich repository of knowledge for those interested in the innovative applications of medical science, contributing significantly to the academic discourse and the practical world of healthcare. With an open access option, it ensures that its valuable content is readily accessible to a global audience, fostering collaborative advancements in modern medical practices.

BIOCELL

Pioneering Discoveries in Molecular Biology
Publisher: TECH SCIENCE PRESSISSN: 0327-9545Frequency: 12 issues/year

BIOCELL is a distinguished peer-reviewed journal dedicated to the field of Cell Biology, published by TECH SCIENCE PRESS. Since its inception in 1995, the journal has been at the forefront of disseminating innovative research, with converged publication years extending from 1995 to 2013 and from 2015 to 2024. Although it currently holds a Q4 ranking in the Cell Biology category according to the 2023 category quartiles, BIOCELL aims to foster advancements by providing a platform for researchers, professionals, and students to share their findings in biochemistry, genetics, and molecular biology. The journal is available in both print (ISSN: 0327-9545) and digital formats (E-ISSN: 1667-5746) and seeks to attract contributions that enhance scholarly dialogue and understandings of cellular mechanisms and innovations. With a commitment to quality research and critical discourse, BIOCELL plays an important role in nurturing the scientific community within Argentina and beyond, offering vital insights that contribute to the advancement of the life sciences.

Biochemistry Moscow-Supplement Series B-Biomedical Chemistry

Advancing Biomedical Insights, One Study at a Time.
Publisher: MAIK NAUKA-INTERPERIODICAISSN: 1990-7508Frequency: 4 issues/year

Biochemistry Moscow-Supplement Series B-Biomedical Chemistry, published by MAIK NAUKA-INTERPERIODICA, is a pivotal journal in the fields of biochemistry, clinical biochemistry, and molecular medicine. Established in 2008, the journal serves as a vital platform for researchers and professionals seeking to disseminate and access groundbreaking research in the biomedical sciences. With an ISSN of 1990-7508 and an E-ISSN of 1990-7516, the journal has been recognized in the Q4 quartile across various categories as of 2023, highlighting its emerging presence in the academic community despite a competitive landscape. Although currently not available as Open Access, the journal encompasses a broad spectrum of studies, ranging from theoretical analysis to practical applications in biomedical research. The journal's dedicated focus on advancing our understanding of biochemical principles positions it as an essential resource for students and professionals alike, enhancing its significance in the global scientific dialogue.